11:15 AM - 11:30 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Mitotherapeutix is a preclinical stage pharmaceutical company that is focused on the development of innovative drugs that can be used to treat metabolic diseases. We are developing an siRNA drug MT-101, expected to be a once a quarter subcutaneous injection for the treatment of NASH.
MT-101 is designed to transiently eliminate a mitochondrial peptide (MCJ) that is a negative regulator of mitochondrial metabolism. Iindividuals that have developed fatty liver disease including NASH typically develop higher levels of MCJ which causes a slowdown in metabolic activity. By removing MCJ, mitochondrial metabolism is turned up resulting in the increased burning of lipids (fat) and the reduction of fibrosiis. This activity and safety has been confirmed in mice, rats ans non human primates. Mitotherapeutix has demonstrated eliminating MCJ can favorably impact multiple factors including lipid levels, triglycerides, liver enzymes and fibrosis. We expect to file an IND in the fourth quarter of 2024
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
MT-101, an siRNA to suppress production of the mitochondrial regulator MCJ ready for GMP production.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
Mitotherapeutix LLC